Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: A novel strategy in drug development

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Stenvang, Jan ^a,b   Kümler, Iben ^c   Nygård, Sune Boris ^a   Smith, David Hersi ^a,d   Nielsen, Dorte ^c   Brünner, Nils ^a,b   Moreira, José M A ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Institute of Cancer Biolog   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AGILENT TECHNOLOGIES   (United States)

Author keywords

Biomarker; Breast cancer; Drug repurposing; Irinotecan; TOP1

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LEVOLEUCOVORIN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TAXANE DERIVATIVE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COLORECTAL CANCER; COPY NUMBER VARIATION; DNA REPLICATION; DNA TRANSCRIPTION; DRUG EFFICACY; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; META ANALYSIS (TOPIC); OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TESTIS TUMOR; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

EID: 84892396862     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00313     Document Type: Review

References (98)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127(12):2893-917. doi: 10.1002/ijc.25516.
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008-2030): a population-based study. Lancet Oncol (2012) 13(8):790-801. doi:10.1016/S1470-2045(12)70211-5.
3. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (2012) 380(9856):1840-50. doi:10.1016/S0140-6736(12)60919-2.
4. Workman P, Clarke PA. Resisting targeted therapy: fifty ways to leave your EGFR. Cancer Cell (2011) 19(4):437-40. doi:10.1016/j.ccr.2011.03.020.
5. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 316(5827):1039-43. doi:10.1126/science.1141478.
6. De Palma M, Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 6(2):111-27. doi:10.1016/j.molonc.2012.01.011.
7. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 480(7377):387-90. doi:10.1038/nature10662.
8. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 468(7326):973-7. doi:10.1038/nature09626.
9. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol (2007) 25(2):209-16. doi:10.1200/JCO.2006.09.0803.
10. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci (2013) 34(9):508-17. doi:10.1016/j.tips.2013.06.005.
11. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov (2013) 12(1):35-50. doi:10.1038/nrd3913.
12. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res (2012) 72(5):1055-8. doi:10.1158/0008-5472.CAN-11-3439.
13. Nair P. Second act: drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs. Proc Natl Acad Sci USA (2013) 110(7):2430-2. doi:10.1073/pnas.201300188.
14. Mullard A. Drug repurposing programmes get lift off. Nat Rev Drug Discov (2012) 11(7):505-6. doi:10.1038/nrd3776.
15. Peters JU. Polypharmacology-foe or friend? J Med Chem (2013) 56(22):8955-71. doi:10.1021/jm400856t.
16. Ekins S, Williams AJ. Finding promiscuous old drugs for new uses. Pharm Res (2011) 28(8):1785-91. doi:10.1007/s11095-011-0486-6.
17. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 12(12):1134-42. doi:10.1016/S1470-2045(11)70231-5.
18. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol (2005) 23(30):7483-90. doi:10.1200/JCO.2005.11.007.
19. Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol (2010) 28(6):984-90. doi:10.1200/JCO.2009.24.1166.
20. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, Group EGW. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 23(Suppl 7):1211-9. doi:10.1093/annonc/mds232.
21. Kumler I, Brunner N, Stenvang J, Balslev E, Nielsen DL. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res Treat (2013) 138(2):347-58. doi:10.1007/s10549-013-2476-3.
22. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer (2006) 6(10):789-802. doi:10.1038/nrc1977.
23. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res (2002) 8(8):2605-11.
24. Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res (2000) 60(17):4725-8.
25. Wu J, Liu LF. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res (1997) 25(21):4181-6. doi:10.1093/nar/25.21.4181.
26. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res (2003) 532(1-2):173-203. doi:10.1016/j.mrfmmm.2003.08.016.
27. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med (2006) 12(9):440-50. doi:10.1016/j.molmed.2006.07.007.
28. Benson AB III, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 11(2):141-52.quiz 52,.
29. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol (2012) 23(10):2479-516. doi:10.1093/annonc/mds236.
30. Seufferlein T. Systemic treatment of advanced pancreatic cancer-step by step progress. Gut (2013) 62(5):660-1. doi:10.1136/gutjnl-2012-303129.
31. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB III, Casper ES, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 10(6):703-13.
32. Available from: http://www.clinicaltrials.gov/.
33. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, et al. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 10(11):1339-49.
34. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 21(Suppl 5):v23-30. doi:10.1093/annonc/mdq244.
35. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-topotecan-hydrochloride/print.
36. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000123/human_med_000823.jsp&mid=WC0b01ac058001d124.
37. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 23(Suppl 7):1227-32.
38. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 24(Suppl 6):699-105.
39. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, et al. Small cell lung cancer. J Natl Compr Canc Netw (2013) 11(1):78-98.
40. Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res (2013) 19(1):268-78. doi:10.1158/1078-0432.CCR-12-1201.
41. Awada A, Garcia AA, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol (2013) 14(12):1216-25. doi:10.1016/S1470-2045(13)70429-7.
42. Von Hoff DD, Jameson GS, Borad MJ, Rosen LS, Utz J, Basche M, et al. First phase I trial of NKTR-102 (Peg-irinotecan) reveals early evidence of broad anti-tumor activity in three different schedules. EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" Poster No.: 595 (2008).
43. Fan B, Dachrut S, Coral H, Yuen ST, Chu KM, Law S, et al. Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. PLoS One (2012) 7(4):e29824. doi:10.1371/journal.pone.0029824.
44. Rømer MU, Jensen NF, Nielsen SL, Müller S, Nielsen KV, Nielsen HJ, et al. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol (2012) 47(1):68-79. doi:10.3109/00365521.2011.638393.
45. Ryan D, Rafferty M, Hegarty S, O'Leary P, Faller W, Gremel G, et al. Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. Pigment Cell Melanoma Res (2010) 23(4):542-53. doi:10.1111/j.1755-148X.2010.00720.x.
46. Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, et al. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res (1994) 54(16):4257-60.
47. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res (2000) 6(5):1833-9.
48. Rømer MU, Nygård SB, Christensen IJ, Nielsen SL, Nielsen KV, Müller S, et al. Topoisomerase 1 (TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol (2012) 7(1):101-11. doi:10.1016/j.molonc.2012.09.001.
49. Smith DH, Christensen IJ, Jensen NF, Markussen B, Rømer MU, Nygård SB, et al. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS One (2013) 8(4):e60613. doi:10.1371/journal.pone.0060613.
50. Stenvang J, Smid M, Nielsen S, Balslev E, Timmermans M, Rømer M, et al. Topoisomerase 1 Gene Copy Aberration is a Frequent Finding in Clinical Breast Cancer Sample. San Antonio: San Antonio Breast Cancer Symposium (2012).
51. Tanner MM, Tirkkonen M, Kallioniemi A, Isola J, Kuukasjärvi T, Collins C, et al. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res (1996) 56(15):3441-5.
52. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut (2009) 58(1):79-89. doi:10.1136/gut.2007.143065.
53. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature (2010) 463(7283):899-905. doi:10.1038/nature08822.
54. Bronstein IB, Vorobyev S, Timofeev A, Jolles CJ, Alder SL, Holden JA. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res (1996) 8(1):17-25.
55. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res (1994) 54(2):539-46.
56. Yu J, Miller R, Zhang W, Sharma M, Holtschlag V, Watson MA, et al. Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics (2008) 9(10):1459-66. doi:10.2217/14622416.9.10.1459.
57. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (1989) 246(4933):1046-8. doi:10.1126/science.2555920.
58. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs (2009) 20(6):519-24. doi:10.1097/CAD.0b013e32832b53ff.
59. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer (1999) 80(3-4):364-70. doi:10.1038/sj.bjc.6690364.
60. Vallbohmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, et al. Molecular determinants of irinotecan efficacy. Int J Cancer (2006) 119(10):2435-42. doi:10.1002/ijc.22129.
61. Tsavaris N, Lazaris A, Kosmas C, Gouveris P, Kavantzas N, Kopterides P, et al. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol (2009) 64(2):391-8. doi:10.1007/s00280-008-0886-4.
62. Gouveris P, Lazaris AC, Papathomas TG, Nonni A, Kyriakou V, Delladetsima J, et al. Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. J Cancer Res Clin Oncol (2007) 133(12):1011-5. doi:10.1007/s00432-007-0253-6.
63. Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol (2002) 33(11):1114-9. doi:10.1053/hupa.2002.129202.
64. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, et al. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer (2004) 111(2):252-8. doi:10.1002/ijc.20208.
65. Staley BE, Samowitz WS, Bronstein IB, Holden JA. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod Pathol (1999) 12(4):356-61.
66. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Matsui N, et al. Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep (2007) 17(5):1045-50.
67. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol (2008) 26(16):2690-8. doi:10.1200/JCO.2007.15.5580.
68. Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, et al. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer (2009) 9:339. doi:10.1186/1471-2407-9-339.
69. van der Zee AG, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PH, et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 51(21):5915-20.
70. Codegoni AM, Castagna S, Mangioni C, Scovassi AI, Broggini M, D'Incalci M. DNA-topoisomerase I activity and content in epithelial ovarian cancer. Ann Oncol (1998) 9(3):313-9. doi:10.1023/A:1008207125986.
71. Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, Bronstein IB. Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol Pathol (1997) 50(5):247-53. doi:10.1136/mp.50.5.247.
72. Monnin KA, Bronstein IB, Gaffney DK, Holden JA. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol (1999) 30(4):384-91. doi:10.1016/S0046-8177(99)90112-0.
73. Coleman LW, Bronstein IB, Holden JA. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer Res (2001) 21(2A):1167-72.
74. Coleman LW, Perkins SL, Bronstein IB, Holden JA. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in testicular seminomas. Hum Pathol (2000) 31(6):728-33. doi:10.1053/hupa.2000.8462.
75. Gupta D, Bronstein IB, Holden JA. Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Hum Pathol (2000) 31(2):214-9. doi:10.1016/S0046-8177(00)80222-1.
76. Lynch BJ, Komaromy-Hiller G, Bronstein IB, Holden JA. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum Pathol (1998) 29(11):1240-5. doi:10.1016/S0046-8177(98)90251-9.
77. Hafian H, Venteo L, Sukhanova A, Nabiev I, Lefevre B, Pluot M. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas. Hum Pathol (2004) 35(6):745-51. doi:10.1016/j.humpath.2004.02.004.
78. Coleman LW, Rohr LR, Bronstein IB, Holden JA. Human DNA topoisomerase I: an anticancer drug target present in human sarcomas. Hum Pathol (2002) 33(6):599-607. doi:10.1053/hupa.2002.124911.
79. Lynch BJ, Bronstein IB, Holden JA. Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J (2001) 7(3):176-80. doi:10.1046/j.1524-4741.2001.007003176.x.
80. Nielsen KV, Brunner N. Re: topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2011) 103(4):352-3. doi:10.1093/jnci/djq528.
81. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 101(21):1446-52. doi:10.1093/jnci/djp335.
82. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet (2007) 370(9582):143-52. doi:10.1016/S0140-6736(07)61087-3.
83. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 370(9582):135-42. doi:10.1016/S0140-6736(07)61086-1.
84. Koopman M, Knijn N, Richman S, Seymour M, Quirke P, van Tinteren H, et al. The correlation between topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG). Eur J Cancer Suppl (2009) 7(2):321-2. doi:10.1016/S1359-6349(09)71098-5.
85. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 27(19):3117-25. doi:10.1200/JCO.2008.21.6663.
86. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol (2007) 25(23):3456-61. doi:10.1200/JCO.2007.11.2144.
87. Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J. When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol (2012) 23(Suppl 10):x349-53. doi:10.1093/annonc/mds297.
88. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res (2009) 15(6):1898-905. doi:10.1158/1078-0432.CCR-08-2033.
89. Bergh J. Quo vadis with targeted drugs in the 21st century? J Clin Oncol (2009) 27(1):2-5. doi:10.1200/JCO.2008.18.8342.
90. Rodon J, Saura C, Dienstmann R, Vivancos A, Ramon y Cajal S, Baselga J, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol (2012) 9(6):359-66. doi:10.1038/nrclinonc.2012.48.
91. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol (2009) 27(24):4027-34. doi:10.1200/JCO.2009.22.3701.
92. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res (2008) 14(14):4358-67. doi:10.1158/078-0432.CCR-08-288.
93. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst (2010) 102(3):152-60. doi:10.1093/jnci/djp477.
94. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res (2012) 18(15):4004-12. doi:10.1158/078-0432.CCR-12-167.
95. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med (2012) 9(5):e1001216. doi:10.1371/journal.pmed.1001216.
96. Ilyas M, Grabsch H, Ellis IO, Womack C, Brown R, Berney D, et al. Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology (2013) 62(6):827-39. doi:10.1111/his.12118.
97. Perego P, Capranico G, Supino R, Zunino F. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs (1994) 5(6):645-9. doi:10.1097/00001813-199412000-00006.
98. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer (1997) 70(3):335-40. doi:10.1002/(SICI)1097-0215(19970127)70:3<335::AID-IJC15>3.3.CO;2-B.